Press release - 18/02/2010 New molecules promise improved diagnosis of pancreatic cancer Being diagnosed with pancreatic cancer is often a death sentence. One reason for the high mortality rate of pancreatic cancer patients is that there is currently no reliable diagnosis of early stages and no cure once the disease has reached a late stage. In an EU-funded project, 23 research groups from six countries have developed new strategies for the improved diagnosis of pancreatic cancer. Researchers at the Ulm-based Hospital for Nuclear…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecules-promise-improved-diagnosis-of-pancreatic-cancer
Press release - 04/02/2010 World Cancer Day: encouraging the prevention, detection and treatment of cancer World Cancer Day on the 4th of February is designed to raise awareness that cancer remains one of the major, often fatal human diseases. Every year, more than twelve million people worldwide develop cancer. The Helmholtz Association carries out research into the development of cancer and the underlying risk factors, and comes up with effective strategies for the prevention of cancer and for better diagnostics and targeted therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/world-cancer-day-encouraging-the-prevention-detection-and-treatment-of-cancer
Press release - 04/02/2010 QIAGEN acquires ESE GmbH QIAGEN N.V. has announced its acquisition of ESE GmbH a privately owned developer and manufacturer of UV and fluorescence optical measurement devices. ESE GmbH is based in Stockach Germany. The cash transaction is valued at up to US19 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/qiagen-acquires-ese-gmbh
Press release - 28/01/2010 Roche invests 86 million Swiss Francs in its Mannheim site Roche is to invest 86 million Swiss Francs (approximately 57.3 million euros) in the construction of a new pharmaceutical production unit at its Mannheim company site. The new production line will deliver the commercial supply of the breast cancer drug Herceptin (trastuzumab) from 2013 onwards.https://www.gesundheitsindustrie-bw.de/en/article/press-release/roche-invests-86-million-swiss-francs-in-its-mannheim-site
Press release - 26/01/2010 MicroTEC Südwest convinces in the second round of the BMBF’s Leading Edge Cluster competition The winners of the second round of the German Federal Ministry of Education and Research’s (BMBF) Leading Edge Cluster competition have now been selected. On 26th January 2010, the chairman of the jury, Prof. Dr. Andreas Barner (spokesperson for the Boehringer Ingelheim GmbH Management Board), and the German Research Minister, Prof. Dr. Annette Schavan, announced in Berlin which of the ten finalists of the highly lucrative Leading Edge Cluster…https://www.gesundheitsindustrie-bw.de/en/article/press-release/microtec-suedwest-convinces-in-the-second-round-of-the-bmbf-s-leading-edge-cluster-competition
Article - 25/01/2010 Intelligent use of suitable biomarkers How quickly does a pharmaceutical substance exert its effect? What mechanisms does it use to exert its effect on people and how long does it remain active? In a team headed by Prof. Dr. Martin Elmlinger Nycomed GmbH has developed an efficient biomarker discovery concept specially adapted to the companys requirements and designed to clarify such questions. The concept is specifically geared to the phases and requirements of the companys projects.…https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-use-of-suitable-biomarkers
Article - 25/01/2010 Treatment and Research Centre of Rare Diseases established in Tübingen On 22nd January 2010, the first German Treatment and Research Centre of Rare Diseases (ZSE) was officially opened in Tübingen. Interdisciplinary teams will from now on be developing new therapies under one roof for around three to four million patients suffering from rare diseases in Germany. The centre in Tübingen will offer optimal patient treatment, coordinate the cooperation between international specialists, and provide competent advice and…https://www.gesundheitsindustrie-bw.de/en/article/news/treatment-and-research-centre-of-rare-diseases-established-in-tuebingen
Press release - 18/01/2010 Measurement instead of culture – rapid detection of Legionella There has been an unusually high frequency of Legionella infections in the city of Ulm in the period since mid-December 2009. The search for the source of the infection is well underway, although the use of traditional detection methods make it a time-consuming process. New screening methods developed by the Fraunhofer IPM could considerably reduce the time required to detect the source of infection.https://www.gesundheitsindustrie-bw.de/en/article/press-release/measurement-instead-of-culture-rapid-detection-of-legionella
Article - 14/12/2009 Clever surveillance system keeps yeast in check The spectrum of human diseases (mycoses) caused by fungi ranges from trivial nail infections to life-threatening systemic infections. The latter are mainly caused by Candida albicans. The dermatologist Prof. Dr. med. Martin Schaller from Tübingen is investigating how this fungus, which is actually part of the normal microbial flora of humans, becomes a pathogen. At the same time, he is looking into the role the patient’s immune system plays in…https://www.gesundheitsindustrie-bw.de/en/article/news/clever-surveillance-system-keeps-yeast-in-check
Press release - 08/12/2009 Official opening of the BioRN Academy in Mannheim On 7th December 2009, the BioRN Academy was opened with an official ceremony at the MAFINEX Technology Centre in Mannheim, Germany. This marks the beginning of a project, which is the only one of its kind in Germany, aimed at the further qualification of life scientists as managers in the biotechnology industry. The Rhine-Neckar Graduate School, Graf & Associate, Roche Diagnostics and the SRH University of Applied Sciences Heidelberg are all…https://www.gesundheitsindustrie-bw.de/en/article/press-release/official-opening-of-the-biorn-academy-in-mannheim
Press release - 07/12/2009 Curetis AG - € 18.5 million Series A Financing Round closed A consortium of leading life-science venture capital funds invests € 18.5 million in the German medical diagnostics company Curetis AG. This financing will enable Curetis to complete development of its innovative diagnostic products through to market entry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-18-5-million-series-a-financing-round-closed
Article - 30/11/2009 BioPharMaXX cluster to strengthen the Ulm region BioRegionUlm recently announced the launch of BioPharMaXX at a meeting held in Ummendorf castle (close to Ulm). The acronym refers to a cluster focusing on biotechnology, pharmacy and medical technology that was selected as one of twelve regional clusters in a state-wide contest in Baden-Württemberg in 2008. Company representatives and researchers presented projects to improve the time-consuming and costly protein purification process used in…https://www.gesundheitsindustrie-bw.de/en/article/news/biopharmaxx-cluster-to-strengthen-the-ulm-region
Article - 28/11/2009 "You cannot afford to fail twice in Germany" Prof. Dr. Bodo Liedvogel and Dr. Heinz Haubruck founded the company DIARECT AG in Freiburg in 1998. They not only brought 20 years of experience in industry to the company but also their entire savings. In the following interview Dr. Heinz Haubruck tells Christoph Bächtle about the return investors expect from companies how to win over potential clients and the risks associated with setting up ones own business.https://www.gesundheitsindustrie-bw.de/en/article/news/you-cannot-afford-to-fail-twice-in-germany
Press release - 24/11/2009 Three new collaborative research centres in Baden-Württemberg The German Research Foundation (DFG) is set to establish 17 new collaborative research centres (SFBs) on 1st January 2010. Ten of the new SFBs will focus on life science research projects, and will initially be funded for a period of four years with a total of 78 million euros in funding. One of the SFBs will be established at the University of Freiburg. Six of the 17 new SFBs are SFB/Transregio projects involving researchers from several German…https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-collaborative-research-centres-in-baden-wuerttemberg
Press release - 23/11/2009 GATC Biotech soon opens sequencing laboratory in London GATC Biotech Europes leading sequencing service provider for industrial and academic research announces that it will open a sequencing laboratory in London to provide scientists in UK and Ireland with single sample sequencing services. The GATC London Laboratory will be situated in the London BioScience Innovation Centre LBIC and will start operations on January 4 2010. https://www.gesundheitsindustrie-bw.de/en/article/press-release/gatc-biotech-soon-opens-sequencing-laboratory-in-london
Article - 05/11/2009 CLAIR provides new insights The human eye is a fascinating organ as well as model for the specialists at Stockach-based Sensovation AG. Their complex optical detection systems are based on CCD and CMOS technologies. However a high-tech sensor is able to recognise much more than many eyes put together. https://www.gesundheitsindustrie-bw.de/en/article/news/clair-provides-new-insights
Press release - 27/10/2009 Precision Diagnosis of Brain Tumors: Antibody to Detect Enzyme Defect More than 100 different types of brain tumor are known in medicine. Their exact diagnosis is often difficult, because only tiny amounts of tumor tissue are usually available. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the University of Heidelberg have developed an antibody which is highly specific for the characteristic alteration of an enzyme that is typical of two dangerous types of brain tumor.…https://www.gesundheitsindustrie-bw.de/en/article/press-release/precision-diagnosis-of-brain-tumors-antibody-to-detect-enzyme-defect
Press release - 20/10/2009 2nd Science to Market Conference The second Science to Market Conference took place in Hannover, Germany, on October 6 – 7, 2009. The aim of the conference was the promotion of cooperation between academia and industry in the area of pharmaceutical biotechnology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/2nd-science-to-market-conference
Press release - 14/10/2009 mtm laboratories Extends Series C Financing Round by EUR 7 Million Bringing Total to EUR 39 Million (USD 57 Million) mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, announced on 14th October the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company’s last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/mtm-laboratories-extends-series-c-financing-round-by-eur-7-million-bringing-total-to-eur-39-million
Press release - 30/09/2009 New managing director for BioRegion Rhein-Neckar-Dreieck e.V. Biotech expert Dr. Julia Schüler is leaving Ernst Young to join BioRegion Rhein-Neckar-Dreieck e.V. Rhine-Neckar BioRegion. The biologist is to succeed Ernst-Dieter Jarasch the associations managing director since its establishment in 1996.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-managing-director-for-bioregion-rhein-neckar-dreieck-e-v
Press release - 24/09/2009 CeGAT: Tracking genes using cutting-edge technologies To adequately meet the growing demand for genetic diagnostics doctor scientist and bioinformatician Dr. Saskia Biskup and her husband business graduate Dr. Dirk Biskup founded the Center for Genomics and Transcriptomics or CeGAT for short in July 2009. As a supplier of DNA and RNA sequencing in the STERN BioRegion CeGAT which is based in the Technology park Tübingen Reutlingen TTR uses state-of-the-art high-throughput technologies to examine…https://www.gesundheitsindustrie-bw.de/en/article/press-release/cegat-tracking-genes-using-cutting-edge-technologies
Press release - 18/09/2009 Why don’t brain tumours respond to drugs? Malignant brain tumours do not often respond to promising new drugs. Researchers from Heidelberg have now uncovered a mechanism and a tumour marker that are linked to the development of this resistance. A “death receptor” might possibly indicate the chances of success of chemotherapy at the same time as providing new approaches for developing a new therapy for the successful treatment of brain tumours.https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-don-t-brain-tumours-respond-to-drugs
Article - 14/09/2009 SensScreen Technologies: Magnetic separation to conquer biotechnological areas of application In terms of protein purification, the biopharmaceutical industry is increasingly reaching its technical and economic limits. The currently used chromatography procedures are expensive, time-consuming and associated with high product losses due to the large number of individual processing steps involved. Special magnetic microparticles, such as those developed by the chemist Dr. Jochen F. Peter with his recently established company SensScreen…https://www.gesundheitsindustrie-bw.de/en/article/news/sensscreen-technologies-magnetic-separation-to-conquer-biotechnological-areas-of-application
Press release - 14/09/2009 Launch of SAFE-T Consortium: Translational Safety Biomarkers "Faster Development of Safer Medicines through Translational Safety Biomarkers": On September 14, 2009, the Safer And Faster Evidence-based Translation (SAFE-T) consortium project under the EU Innovative Medicines Initiative - Joint Undertaking (IMI-JU) was presented at the EUROTOX 2009 conference in Dresden. The consortium announces the start of work to qualify biomarkers for drug-induced kidney, liver and vascular injury in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/launch-of-safe-t-consortium-translational-safety-biomarkers
Article - 03/09/2009 Company establishment with combined forces The company DSL a specialist in molecular diagnostics is currently being established in the city of Eriskirch close to Friedrichshafen Germany. The future managing directors Dr. Sabine Lautenschläger and Dr. Daniel Schaarschmidt are being supported by the BioLAGO network and the pharmaceutical company Nycomed.https://www.gesundheitsindustrie-bw.de/en/article/news/company-establishment-with-combined-forces